Over the last 7 days, the United States market has experienced a 1.8% drop, yet it remains up by 11% over the past year with earnings forecasted to grow by 17% annually. In such a fluctuating environment, identifying stocks that are potentially undervalued can offer investors opportunities to capitalize on discrepancies between current prices and estimated values, as seen with companies like Amazon.com and others.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zions Bancorporation National Association (ZION) | $63.14 | $123.63 | 48.9% |
| Sociedad Química y Minera de Chile (SQM) | $60.13 | $118.52 | 49.3% |
| Northeast Bank (NBN) | $124.75 | $240.74 | 48.2% |
| Live Oak Bancshares (LOB) | $34.45 | $68.81 | 49.9% |
| KeyCorp (KEY) | $19.92 | $39.34 | 49.4% |
| Insteel Industries (IIIN) | $29.53 | $57.65 | 48.8% |
| Futu Holdings (FUTU) | $105.50 | $207.26 | 49.1% |
| First Solar (FSLR) | $171.80 | $331.71 | 48.2% |
| Civista Bancshares (CIVB) | $26.69 | $53.30 | 49.9% |
| Addus HomeCare (ADUS) | $115.16 | $226.18 | 49.1% |
Here we highlight a subset of our preferred stocks from the screener.
Overview: Amazon.com, Inc. operates in the retail sale of consumer products, advertising, and subscription services through both online and physical stores globally, with a market capitalization of approximately $2.70 trillion.
Operations: The company's revenue is derived from several segments, including $173.61 billion from International operations, $453.67 billion from North America, and $148.40 billion from Amazon Web Services (AWS).
Estimated Discount To Fair Value: 44.6%
Amazon's stock is trading significantly below its estimated future cash flow value, suggesting potential undervaluation. Despite a forecasted revenue growth rate of 12.7% annually, which is slower than the broader US market, Amazon's earnings have shown strong recent growth and are expected to continue increasing at a moderate pace. Recent developments include strategic acquisitions in AI technology and exclusive product launches in collaboration with major brands, potentially enhancing its competitive edge and operational efficiency.
Overview: Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutics across the United States, Europe, Canada, and Japan with a market cap of $22.92 billion.
Operations: The company generates revenue of $5.82 billion from its Oncology and Dermatology Pharmaceutical Products segment.
Estimated Discount To Fair Value: 32.8%
Incyte's stock is trading at a notable discount to its estimated future cash flow value, indicating potential undervaluation. Despite recent earnings growth of 85.1%, forecasts suggest declines in revenue and earnings over the next three years. Recent FDA approval of Atebrioz™ for Fibrodysplasia Ossificans Progressiva and upcoming presentations at the ESMO Congress highlight ongoing product development efforts, which could impact future cash flows positively despite current insider selling trends.
Overview: NXP Semiconductors N.V. is a global provider of semiconductor products, operating in regions such as the United States, Germany, Japan, and China, with a market cap of approximately $58.03 billion.
Operations: The company's revenue is primarily derived from its High Performance Mixed Signal (HPMS) segment, which generated $13.19 billion.
Estimated Discount To Fair Value: 10.1%
NXP Semiconductors is trading at US$230.19, below its estimated future cash flow value of US$256.07, reflecting potential undervaluation. Despite high debt levels, the company has shown strong earnings growth and is projected to continue growing at 12.95% annually. Recent business expansions in Malaysia and strategic partnerships with companies like Variscite Ltd., alongside a robust automotive chip segment, bolster its long-term prospects amidst slower-than-market revenue growth forecasts.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com